Prognostic factors of invasive non-Hodgkin's lymphoma.
- Author:
Hui YU
1
;
Xiao-Nan HONG
;
Jin LI
;
Li-Ping PENG
;
Lan YE
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Combined Modality Therapy; statistics & numerical data; Cyclophosphamide; therapeutic use; Disease-Free Survival; Doxorubicin; analogs & derivatives; therapeutic use; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; drug therapy; pathology; radiotherapy; Lymphoma, Non-Hodgkin; drug therapy; pathology; radiotherapy; Male; Middle Aged; Neoplasm Staging; Prednisone; therapeutic use; Prognosis; Proportional Hazards Models; Remission Induction; Retrospective Studies; Vincristine; therapeutic use
- From: Chinese Journal of Oncology 2007;29(6):461-463
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEThere is heterogeneity in non-Hodgkin's lymphoma. The purpose of this study is to investigate the prognostic factors of invasive non-Hodgkin's lymphoma.
METHODSFrom June 2002 to June 2006, 137 patients with invasive non-Hodgkin's lymphoma were treated by regular regimen consisting of radiotherapy and chemotherapy. The clinical data including prognostic factors was analyzed by SPSS 10.0.
RESULTSAfter treated with chemotherapy and radiotherapy, 35 (25.5%) patients achieved CR, 67 (48.9%) PR, 6 (4.3%) SD, 29 (21.2%) PD, ORR (objective response rate) of this series was 74.5%. The overall 4-year survival rate was 70.8%. The PFS (prognosis free survival) was 42.7%. Multivariate analysis using Cox model indicated that clinical stage III-IV, PS score > or = 2, more than 2 external nodal involvement were closely correlated with overall survival.
CONCLUSIONThe overall survival of invasive non-Hodgkin's lymphoma treated with present combined therapy regimen has been improved greatly. However, further investigation is still needed for exploring more effective individualized treatment regimen.
